Trial Profile
A first-in-human safety and tolerability study of Patiromer in healthy subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 May 2016
Price :
$35
*
At a glance
- Drugs Patiromer (Primary)
- Indications Hyperkalaemia
- Focus Adverse reactions; First in man
- 22 May 2016 According to a Relypsa media release, data from this trial were presented at the 53rd Congress of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA).
- 22 May 2016 Results published in the Relypsa media release.
- 28 Apr 2016 Results of new analyses from this and another phase I trial (CT profile 268636) published in a Relypsa Inc. media release.